The trademark application my T Cell was filed by Klinikum der Universität München Anstalt des öffentlichen Rechts, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on April 20, 2021, and it was registered by office on July 28, 2021 without any oppositions.
The application was filed in German (English was selected as the second language).
Goods And Services
The mark was filed in class 9 with following description of goods:
Mobile apps to support medical and diagnostic applications in the field of cancer immunotherapy
Mobile apps to support medical and diagnostic applications in the field of bi-specific T-cell engagers and CAR T-cell therapy
Mobile apps for monitoring and treatment of toxicity released by bi-specific T-cell engagers and CAR T-cell therapy
Mobile apps for training specialised medical personnel
Mobile apps for training specialised medical personnel in the field of cancer immunotherapy, in particular in the field of bi-specific T-cell engagers and CAR T-cell therapy
Mobile apps for evaluating, monitoring and managing medical data, in particular medical data relating to the treatment of toxicity released by bi-specific T-cell engagers and CAR T-cell therapy
Mobile apps for medical and diagnostic purposes, namely for use in transferring data from medical devices to electronic data management systems
Mobile apps for creating and exchanging a disease journal and a connection to external databases and apparatus for the aforesaid
Computer software to support medical and diagnostic applications in the field of cancer immunotherapy
Computer software to support medical and diagnostic applications in the field of bi-specific T-cell engagers and CAR T-cell therapy
Computer software for monitoring and treatment of toxicity released by bi-specific T-cell engagers and CAR T-cell therapy
Computer software for training specialised medical personnel
Computer software for training specialised medical personnel in the field of cancer immunotherapy, in particular in the field of bi-specific T-cell engagers and CAR T-cell therapy
Computer software for evaluating, monitoring and managing medical data, in particular medical data relating to the toxicity released by treatment with bi-specific T-cell engagers and CAR T-cell therapy
Computer software for medical and diagnostic purposes, namely, for use in transferring data from medical devices to electronic data management systems
Computer software for creating and exchanging a disease journal and a connection to external databases and apparatus for the aforesaid.
The mark was filed in class 38 with following description of goods:
Providing of access to a medical care system by means of a mobile app
Providing of access to a medical care system by means of computer software
Providing of access to platforms and portals on the internet in the field of medicine, In particular in the field of bi-specific T-cell engagers and CAR T-cell therapy
Providing of access to information on the internet and other data networks in the field of medicine, In particular in the field of bi-specific T-cell engagers and CAR T-cell therapy and toxicity released by bi-specific T-cell engagers and CAR T-cell therapy
Providing of access to mobile apps and computer programs in data networks for training specialised medical personnel and patients relating to bi-specific T-cell engagers and CAR T-cell therapy and toxicity released by bi-specific T-cell engagers and CAR T-cell therapy
Providing of access to programs and databases for exchanging information among users of a computer network (online forum) in the field of health and medicine, In particular in the field of bi-specific T-cell engagers and CAR T-cell therapy and toxicity released by bi-specific T-cell engagers and CAR T-cell therapy.
The mark was filed in class 44 with following description of goods: